PTX — Prescient Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$56.78m
- AU$47.98m
- AU$0.14m
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial
Australia's Prescient Therapeutics hits two-year high on EU nod for cancer therapy
Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy
Brief: Prescient Therapeutics Secures EU Orphan Drug Designation For PTX-100
Brief: Prescient Therapeutics Seeks Trading Halt
Australia's Prescient Therapeutics falls on discounted capital raise
Brief: Prescient Therapeutics To Raise A$7 Million
Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug
Brief: Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation
Brief: Prescient Therapeutics Says Steven Engle To Retire As Chair
Brief: Prescient Therapeutics Says OmniCAR Technical Issues Resolved
Brief: Prescient Therapeutics Appoints James Mcdonnell As Chief Executive Officer
Brief: Prescient Therapeutics Says CEO To Step Down In Early 2025
Brief: Prescient Therapeutics Says FY Net Loss After Tax A$7.0 Mln
Virax gains on agreement to distribute Marburg virus test kits
Australia's Prescient Therapeutics rises on positive result from drug expansion study